Michael H Fisher

This inventor holds 67 USPTO granted patents and 4 published patent applications, plus 1 CIPO patent and 1 EPO patent, primarily in Pharmaceutical Chemistry (CPC class 5143). Top assignees: Merck + Co., Inc., Evotec Oai, Merial Limited. Active years: 1977-2009.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Michael H Fisher. Retrieved from https://idiyas.com/inventor/michael-h-fisher

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 67 (Patent Applications = 4)

% Patents Active = 97.0

CIPO Patents = 1 (Patent Applications = 3)

EPO Patents = 1

Average Co-Inventor Count = 3.1

ph-index = 21

Forward Citations = 1,171(Granted Patents)

Forward Citations (Not Self Cited) = 1,137(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Somerville, NJ (US) (1977 - 1978)
Bridgewater, NJ (US) (1977 - 1982)
Ringoes, NJ (US) (1980 - 2009)

Company Filing History:

where one patent can have more than one assignee

Years Active: 1977-2009

Loading Chart...

Areas of Expertise:

Sodium Channel Blockers

Antiprotozoal Agents

Dipeptidyl Peptidase Inhibitors

Ocular Hypertension

Beta-Adrenergic Agonists

Nodulisporic Acid Derivatives

Growth Hormone Release

Immunosuppressive Activity

Heterocyclic Compounds

Morpholine Derivatives

Avermectin Derivatives

67 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 7589116 - Biaryl substituted pyrazoles as sodium channel blockers (2009-09-15),

2. 7504501 - Antiprotozoal imidazopyridine compounds (2009-03-17),

3. 7414067 - Ophthalmic compositions for treating ocular hypertension (2008-08-19),

4. 7125873 - Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes (2006-10-24),

5. 6699871 - Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes (2004-03-02),

6. 6586452 - C1 to C4 side chain modified nodulisporic acid analogs (2003-07-01),

7. 6528531 - Aliphatic hydroxy substituted piperidyl diaryl pyrrole derivatives as antiprotozoal agents (2003-03-04),

8. 6399786 - Nonacyclic nodulisporic acid derivatives (2002-06-04),

9. 6291480 - Diaryl piperidyl pyrrole derivatives as antiprotozoal agents (2001-09-18),

10. 6221894 - Nodulisporic acid derivatives (2001-04-24),

11. 6200957 - Antagonists of gonadotropin releasing hormone (2001-03-13),

12. 6197975 - Antagonists of gonadotropin releasing hormone (2001-03-06),

13. 6159975 - Antagonists of gonadotropin releasing hormone (2000-12-12),

14. 6034106 - Oxadiazole benzenesulfonamides as selective .beta..sub.3 Agonist for the (2000-03-07),

15. 5962499 - Nodulisporic acid derivatives (1999-10-05),

Title: **Michael H. Fisher: Innovator in Pharmaceutical Chemistry**

Introduction

Michael H. Fisher, based in Ringoes, NJ, is an accomplished inventor with a remarkable portfolio that includes 67 patents. His innovative work primarily focuses on developing new pharmaceutical compounds that address various medical conditions, particularly in the realm of pain management and the treatment of protozoal diseases.

Latest Patents

Among his recent patents, two significant contributions stand out. The first is the invention of biaryl substituted pyrazoles, which serve as sodium channel blockers. These compounds provide a therapeutic avenue for treating pain, including acute, chronic, visceral, inflammatory, and neuropathic pain. They can be used alone or in combination with other therapeutically active compounds alongside a pharmaceutically acceptable carrier.

The second notable patent involves antiprotozoal imidazopyridine compounds, which are aimed at treating and preventing protozoal diseases in mammals and birds. This innovation includes effective methodologies for controlling coccidiosis in poultry and treatments for various human protozoal infections such as toxoplasmosis and malaria. These compounds can also be administered alongside other anticoccidial agents to enhance their effectiveness.

Career Highlights

Michael H. Fisher has contributed significantly to the pharmaceutical field, having worked with prestigious companies such as Merck & Company and Merial Limited. His expertise in drug formulation and development has not only resulted in numerous patents but has also had a considerable impact on public health.

Collaborations

Throughout his career, Michael has collaborated with esteemed colleagues, including Matthew J. Wyvratt and Helmut H. Mrozik. These collaborations have fostered innovative approaches and ideas that have propelled forward-thinking solutions in pharmaceutical sciences.

Conclusion

Michael H. Fisher exemplifies the essence of innovation in pharmaceutical chemistry. His extensive patent portfolio and dedicated collaboration with industry professionals underscore his commitment to advancing medical treatments. His work continues to inspire and pave the way for future developments that may one day revolutionize the way we approach the treatment of pain and protozoal diseases.

Profile summary based on public USPTO records.